What Coronavirus 3C-like Protease Tells Us: From Structure, Substrate Selectivity, to Inhibitor Design

Overview

Journal Med Res Rev

Publisher Wiley

Specialties General Medicine
Pharmacology

Date 2021 Jan 18

PMID 33460213

Citations 62

Authors

Muya Xiong

Haixia Su

WenFeng Zhao

Hang Xie

Qiang Shao

Yechun Xu

Affiliations

Soon will be listed here.

Abstract

The emergence of a variety of coronaviruses (CoVs) in the last decades has posed huge threats to human health. Especially, the ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to more than 70 million infections and over 1.6 million of deaths worldwide in the past few months. None of the efficacious antiviral agents against human CoVs have been approved yet. 3C-like protease (3CL ) is an attractive target for antiviral intervention due to its essential role in processing polyproteins translated from viral RNA, and its conserved structural feature and substrate specificity among CoVs in spite of the sequence variation. This review focuses on all available crystal structures of 12 CoV 3CL s and their inhibitors, and intends to provide a comprehensive understanding of this protease from multiple aspects including its structural features, substrate specificity, inhibitor binding modes, and more importantly, to recapitulate the similarity and diversity among different CoV 3CL s and the structure-activity relationship of various types of inhibitors. Such an attempt could gain a deep insight into the inhibition mechanisms and drive future structure-based drug discovery targeting 3CL s.

Citing Articles

Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds.

Lu J, Tang Y, Li H, Chen X, Qin P, Xu J Int J Mol Sci. 2025; 26(5).

PMID: 40076865 PMC: 11900932. DOI: 10.3390/ijms26052243.

Predictive Assessment of the Antiviral Properties of against SARS-CoV-2.

Tatsing Foka F, Tumelo Mufhandu H Adv Virol. 2024; 2024:8598708.

PMID: 39135917 PMC: 11317227. DOI: 10.1155/2024/8598708.

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling.

Alvarez N, Adam G, Howe J, Sharma V, Zimmerman M, Dolgov E Viruses. 2024; 16(7).

PMID: 39066320 PMC: 11281459. DOI: 10.3390/v16071158.

Computational Insights into SARS-CoV-2 Main Protease Mutations and Nirmatrelvir Efficacy: The Effects of P132H and P132H-A173V.

Xia Y, Du W, Li Y, Tao Y, Zhang Z, Liu S J Chem Inf Model. 2024; 64(13):5207-5218.

PMID: 38913174 PMC: 11235099. DOI: 10.1021/acs.jcim.4c00334.

Analysis of SARS-CoV-2 Mutations after Nirmatrelvir Treatment in a Lung Cancer Xenograft Mouse Model.

Kang B, Kim D, Kim J, Baek K, Park S, Shin H Biomol Ther (Seoul). 2024; 32(4):481-491.

PMID: 38835145 PMC: 11214963. DOI: 10.4062/biomolther.2023.195.

References

Muramatsu T, Takemoto C, Kim Y, Wang H, Nishii W, Terada T . SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity. Proc Natl Acad Sci U S A. 2016; 113(46):12997-13002. PMC: 5135343. DOI: 10.1073/pnas.1601327113. View

Huang C, Wei P, Fan K, Liu Y, Lai L . 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry. 2004; 43(15):4568-74. DOI: 10.1021/bi036022q. View

Dai W, Zhang B, Jiang X, Su H, Li J, Zhao Y . Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020; 368(6497):1331-1335. PMC: 7179937. DOI: 10.1126/science.abb4489. View

Zhao Q, Li S, Xue F, Zou Y, Chen C, Bartlam M . Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1. J Virol. 2008; 82(17):8647-55. PMC: 2519634. DOI: 10.1128/JVI.00298-08. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Chen S, Chen L, Tan J, Chen J, Du L, Sun T . Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization. Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations. J Biol Chem. 2004; 280(1):164-73. PMC: 7982548. DOI: 10.1074/jbc.M408211200. View

St John S, Therkelsen M, Nyalapatla P, Osswald H, Ghosh A, Mesecar A . X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug design. Bioorg Med Chem Lett. 2015; 25(22):5072-7. PMC: 5896745. DOI: 10.1016/j.bmcl.2015.10.023. View

Hu T, Zhang Y, Li L, Wang K, Chen S, Chen J . Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure. Virology. 2009; 388(2):324-34. PMC: 7103376. DOI: 10.1016/j.virol.2009.03.034. View

Wei P, Fan K, Chen H, Ma L, Huang C, Tan L . The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase. Biochem Biophys Res Commun. 2005; 339(3):865-72. PMC: 7092940. DOI: 10.1016/j.bbrc.2005.11.102. View

10.

Tomar S, Johnston M, St John S, Osswald H, Nyalapatla P, Paul L . Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. J Biol Chem. 2015; 290(32):19403-22. PMC: 4528106. DOI: 10.1074/jbc.M115.651463. View

11.

Kim Y, Liu H, Galasiti Kankanamalage A, Weerasekara S, Hua D, Groutas W . Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016; 12(3):e1005531. PMC: 4814111. DOI: 10.1371/journal.ppat.1005531. View

12.

Ren Z, Yan L, Zhang N, Guo Y, Yang C, Lou Z . The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease. Protein Cell. 2013; 4(4):248-50. PMC: 4875521. DOI: 10.1007/s13238-013-2841-3. View

13.

Chen S, Jonas F, Shen C, Hilgenfeld R, Higenfeld R . Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode. Protein Cell. 2011; 1(1):59-74. PMC: 4875104. DOI: 10.1007/s13238-010-0011-4. View

14.

Zhu L, George S, Schmidt M, Al-Gharabli S, Rademann J, Hilgenfeld R . Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Res. 2011; 92(2):204-12. PMC: 7114241. DOI: 10.1016/j.antiviral.2011.08.001. View

15.

Liang P . Characterization and inhibition of SARS-coronavirus main protease. Curr Top Med Chem. 2006; 6(4):361-76. DOI: 10.2174/156802606776287090. View

16.

Zhao Q, Weber E, Yang H . Recent developments on coronavirus main protease/3C like protease inhibitors. Recent Pat Antiinfect Drug Discov. 2013; 8(2):150-6. DOI: 10.2174/1574891x113089990017. View

17.

Solowiej J, Thomson J, Ryan K, Luo C, He M, Lou J . Steady-state and pre-steady-state kinetic evaluation of severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro cysteine protease: development of an ion-pair model for catalysis. Biochemistry. 2008; 47(8):2617-30. DOI: 10.1021/bi702107v. View

18.

Woo P, Lau S, Lam C, Lau C, Tsang A, Lau J . Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and.... J Virol. 2012; 86(7):3995-4008. PMC: 3302495. DOI: 10.1128/JVI.06540-11. View

19.

Wang F, Chen C, Tan W, Yang K, Yang H . Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design. Sci Rep. 2016; 6:22677. PMC: 4780191. DOI: 10.1038/srep22677. View

20.

Verschueren K, Pumpor K, Anemuller S, Chen S, Mesters J, Hilgenfeld R . A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters. Chem Biol. 2008; 15(6):597-606. PMC: 7110992. DOI: 10.1016/j.chembiol.2008.04.011. View